← back to search

Pedro Berraondo

Instituto de Salud Pública de Navarra ·
Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Immune Cell Function and Interaction.
h-index
44
citations
9,783
works
373
NIH funding
primary concept
email

Recent publications

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
Cell Reports Medicine 2026cited by 0position: middledoi
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 0position: middledoi
Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure
Molecular Therapy — Nucleic Acids 2023cited by 31position: lastdoi
Opportunities and challenges of bi-specific antibodies
International review of cell and molecular biology 2022cited by 25position: middledoi
A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes
Journal of Biological Chemistry 2022cited by 9position: middledoi
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
Journal for ImmunoTherapy of Cancer 2021cited by 41position: middledoi
Advances in mRNA-based drug discovery in cancer immunotherapy
Expert Opinion on Drug Discovery 2021cited by 28position: lastdoi
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Immunity 2020cited by 749position: middledoi
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Molecular Cancer Therapeutics 2019cited by 99position: middledoi
An RNA toolbox for cancer immunotherapy
Nature Reviews Drug Discovery 2018cited by 225position: middledoi
Myeloid-derived cells are key targets of tumor immunotherapy
OncoImmunology 2014cited by 52position: lastdoi
Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases
PLoS ONE 2014cited by 15position: lastdoi
Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies
The AAPS Journal 2013cited by 31position: middledoi
High-density lipoproteins delivering interleukin-15
OncoImmunology 2013cited by 4position: lastdoi
Changing the Tumor Microenvironment: New Strategies for Immunotherapy
Cancer Research 2012cited by 28position: firstdoi
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin
OncoImmunology 2012cited by 10position: lastdoi
Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells
OncoImmunology 2012cited by 6position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Ignacio Melero · Breast Cancer Research Foundation7 papers (2012–2023)Fernando Aranda · Gene Therapy Laboratory4 papers (2014–2023)José Medina‐Echeverz · Center for Cancer Research3 papers (2012–2014) · 3 papers (2021–2023)Aina Segués · Utrecht University3 papers (2021–2023) · 3 papers (2019–2023)María E. Rodríguez-Ruiz · Navarre Institute of Health Research2 papers (2019–2021) · 2 papers (2021–2023)Iñaki Etxeberría · Parker Institute for Cancer Immunotherapy2 papers (2018–2019)Shuyu Huang · Utrecht University2 papers (2022–2023) · 2 papers (2014–2023) · 2 papers (2014–2023) · 2 papers (2022–2023) · 2 papers (2021–2023)Miguel F. Sanmamed · University of Bari Aldo Moro2 papers (2019–2021) · 2 papers (2021–2023) · 2 papers (2021–2023)Dietmar M. Zaiss · Utrecht University2 papers (2022–2022)María C. Ochoa · Gene Therapy Laboratory2 papers (2013–2021)Maite Álvarez · University of California, Davis2 papers (2021–2023)